Skip to main content

Table 2 Baseline socio-demographic and clinical characteristics of participants and 6-month outcome

From: The impact of gender and the social determinants of health on the clinical course of people living with HIV in Myanmar: an observational study

Variable

All patients

n = 221

Poor outcomea

n = 94

Good outcome

n = 87

p

Age

37 (32–46)

39 (33–47)

36 (33–44)

0.29

Male gender

138 (62%)

68 (72%)

46 (53%)

0.007

Unmarried

106 (48%)

45 (48%)

45 (52%)

0.61

Unemployed

53 (24%)

21 (22%)

20 (23%)

 0.92

Living outside Yangon

54 (24%)

25 (27%)

18 (21%)

0.35

Did not complete high school

153 (70%)

64/92 (70%)

62/87 (71%)

0.80

Number of family members living at home

3 (2–4)

3 (2–4)

4 (2–5)

0.49

Per-capita household income (USD)

48.07 (30.77–76.92)

46.15 (30.77–76.92)

51.28 (28.04–76.92)

0.31

Hazardous alcohol consumption

47/220 (21%)

20/94 (21%)

15/86 (17%)

 0.52

Current cigarette smoker

56/211 (27%)

27/89 (30%)

16/82 (20%)

 0.12

Active injecting drug use

3 (1%)

1 (1%)

2 (2%)

0.61

Presently chewing betel nut

77/200 (39%)

37/84 (44%)

26/77 (34%)

 0.18

Hepatitis B surface antigen positive

21/206 (10%)

7/89 (8%)

7/77 (9%)

0.79

Hepatitis C antibody positive

6/206 (3%)

2/89 (2%)

2/77 (3%)

1.0

Body mass index (kg/m2)

19.1 (17.0–22.3)

19.5 (16.6–22.6)

19.5 (17.3–22.1)

0.77

Mean arm circumference (cm)

25 (22–27)

25 (22–28)

24 (22–27)

0.70

WHO stage at enrolment

1 (1–3)

1 (1–3)

1 (1–2)

0.25

CD4 cell count (cells/mm3)

92 (44–158)

86 (41–145)

99 (47–158)

0.25

Receiving dolutegravir containing regimen

181/219 (83%)

78/93 (84%)

76/87 (87%)

0.51

Haemoglobin (g/dL)

11.0 (9.6–12.8)

10.4 (9.6–12.2)

11.0 (9.7–12.9)

0.33

Creatinine (µmol/L)

88 (75–107)

91 (77–111)

91 (75–107)

0.61

  1. All numbers represent absolute numbers (%) or median (interquartile range)
  2. aDefined as death, hospitalisation, loss to follow-up or detectable viral load at 6 months